Related Experiment Video

Updated: May 21, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

[Protein tyrosine kinase inhibitors in cancer therapy]

S Boutayeb1, F Z Zakkouri, M Aitelhaj

  • 1Service d'oncologie médicale, institut national d'oncologie, CHU Ibn Sina, Rabat, Maroc. boutayebdr@yahoo.fr

Pathologie-Biologie
|June 30, 2012
PubMed

Insights

Tyrosine kinase inhibitors (TKI) are small molecule drugs that block cancer-driving enzymes. These targeted therapies are effective against various cancers by inhibiting mutated tyrosine kinases involved in tumor progression.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Context:

  • Tyrosine kinases (TK) are key enzymes in cellular signal transduction.
  • Aberrant TK activity, often due to mutations, drives cancer development and progression.
  • Small molecule tyrosine kinase inhibitors (TKI) have emerged as a significant therapeutic class.

Purpose:

  • To review the role and clinical application of tyrosine kinase inhibitors (TKI) in cancer therapy.
  • To highlight the mechanism of action of TKI targeting constitutively active tyrosine kinases.
  • To discuss the current landscape of approved and developing TKI treatments for various cancers.

Summary:

  • Tyrosine kinase inhibitors (TKI) are low molecular weight drugs that selectively inhibit tyrosine kinases.
  • Their efficacy is pronounced when targeting mutated TK that act as master genes in cancer.
  • TKI represent a crucial advancement in the oncological armamentarium, with numerous agents approved and in development.

Impact:

  • TKI have revolutionized cancer treatment by offering targeted therapies with improved efficacy and reduced toxicity.
  • The development of TKI has led to better outcomes for patients with specific genetic alterations in their tumors.
  • Ongoing research continues to expand the utility of TKI in combination therapies and for new cancer indications.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: